Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenobamate - SK biopharmaceuticals

Drug Profile

Cenobamate - SK biopharmaceuticals

Alternative Names: ONO-2017; ONTOZRY; X-Copri; XCOPRI; YKP-3089

Latest Information Update: 18 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK biopharmaceuticals
  • Developer Angelini Pharmaceuticals; Arvelle Therapeutics; Endo Ventures; SK biopharmaceuticals; SK Life Science
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Anxiolytics; Carbamates; Chlorobenzenes; Mood stabilisers; Small molecules; Tetrazoles
  • Mechanism of Action GABA A receptor modulators; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Partial epilepsies
  • Phase III Tonic-clonic epilepsy
  • Phase II Anxiety disorders; Bipolar disorders; Neuropathic pain

Most Recent Events

  • 11 Apr 2024 US FDA approves cenobamate for alternate methods of administration for treatment of Partial epilepsies in USA
  • 13 Mar 2024 SK biopharmaceuticals expects to launch for Partial epilepsies in Israel in April 2024
  • 22 Jan 2024 Launched for Partial epilepsies (Adjunctive treatment) in Canada (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top